R&D Why are eCOA studies still so challenging? Although eCOA has been in clinical trials for decades, we continue to hit the same road blocks during operational set-up and implementation.
News Roche's KRAS drug tops its rivals in lung cancer trial Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.
News Despite study bust, Vistagen still hopes to file anxiety dru... Vistagen has chalked up another trial failure for fasedienol, its drug candidate for social anxiety disorder.
News Drugmakers asked to defend Chinese trials; reports The House China Select Committee has quizzed MSD, AbbVie, Bristol Myers Squibb, and Pfizer about the ethics of clinical trials run in China.
News Brukinsa data raises chemo-free hope for mantle cell lymphom... Patients with newly diagnosed mantle cell lymphoma could avoid chemotherapy with a regimen based on BeOne's Brukinsa, according to the MANGROVE trial.
News Sanofi eyes extending Nexviazyme into infantile Pompe Armed with new phase 3 data, Sanofi will try to expand the US label of its Pompe disease drug Nexviazyme to include the severe infantile-onset form.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
